Copilot
Su complemento de IA para todos los días
Aproximadamente 105.000 resultados
  1. europa.eu
    https://www.ema.europa.eu/en/documents/product-in… · Archivo PDF

    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS - European …

    Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4.2). Non-small cell lung cancer (NSCLC)

    Explorar más

    Enhertu | European Medicines Agency
    ema.europa.eu
    Enhertu (trastuzumab deruxtecan - European Medicines …
    ema.europa.eu
    Enhertu 100 mg powder for concentrate for solution for …
    medicines.org.uk
    Enhertu approved in the EU as the first HER2-directed …
    astrazeneca.com
    Enhertu: Package Insert - Drugs.com
    drugs.com
    Recomendado para ti en función de lo que es popular • Comentarios
  2. europa.eu
    https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu

    Enhertu | European Medicines Agency

    Explorar más

    Enhertu approved in the EU for the treatment of HER2 …
    astrazeneca.com
    EMA Recommends Extension of Therapeutic Indications for …
    esmo.org
    Recomendado para ti en función de lo que es popular • Comentarios
  3. Preguntas relacionadas
    What is enhertu used for?
    ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy [see Dosage and Administration (2.1)].

    ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for 2.3

    accessdata.fda.gov
    Can enhertu be used as monotherapy for HER2 low breast cancer?
    Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4.2).

    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS - European Medic…

    ema.europa.eu
    Is enhertu safe for patients with her2m advanced or metastatic NSCLC?
    DESTINY-Lung02 is a global, randomised Phase II trial evaluating the safety and efficacy of Enhertu in patients with HER2m advanced or metastatic NSCLC with disease recurrence or progression during or after at least one regimen of prior anticancer therapy that must have contained a platinum-based chemotherapy.

    Enhertu approved in the EU as the first HER2-directed therapy for

    astrazeneca.com
    Can enhertu be used as monotherapy for advanced NSCLC?
    Enhertu as monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.

    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS - European Medic…

    ema.europa.eu
    Comentarios
  4. medicines.org.uk
    https://www.medicines.org.uk/emc/product/…

    Enhertu 100 mg powder for concentrate for solution …

    WEB2 de abr. de 2024 · Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or …

    Explorar más

    NICE recommends Enhertu for more people with advanced …
    nice.org.uk
    Enhertu: Uses, Dosage, Side Effects, Warnings - Drugs.com
    drugs.com
    Recomendado para ti en función de lo que es popular • Comentarios
  5. fda.gov
    https://www.accessdata.fda.gov/drugsatfda_docs/label… · Archivo PDF

    ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for 2.3 ...

  6. AstraZeneca
    https://www.astrazeneca.com/media-centre/press-releases/2023/en…

    Enhertu approved in the EU as the first HER2-directed therapy for ...

  7. europa.eu
    https://www.ema.europa.eu/en/documents/smop/chm… · Archivo PDF

    Enhertu, INN-trastuzumab deruxtecan - European Medicines Agency

  8. medicines.org.uk
    https://www.medicines.org.uk/emc/product/12135/pil

    Enhertu 100 mg powder for concentrate for solution for infusion

  9. AstraZeneca
    https://www.astrazeneca.com/media-centre/press-releases/2023/en…

    Enhertu approved in the EU as the first HER2-directed therapy for ...

  10. daiichi-sankyo.de
    https://www.daiichi-sankyo.de/.../Onkologie/FI_Enhert… · Archivo PDF

    FACHINFORMATION Enhertu 100 mg Pulver für ein Konzentrat zur ...

  11. AstraZeneca
    https://www.astrazeneca.com/media-centre/press-releases/2021/en…

    Enhertu additional analyses further reinforce ground-breaking …